Suppliers / MSN Organics

MSN Organics

India Updated 9 July 2026

MSN Organics is an API manufacturer based in India. It holds 32 active US drug master files and 11 valid CEPs across a filed portfolio of 26 molecules. Its most recent recorded inspection, by US FDA, closed on 31 March 2023 as VAI. Customs aggregates show $16.1M of exports covering 338 molecules to 39 destinations in 2025.

32
active US DMFs
11
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 31 March 2023 VAI US FDA
  • 11 March 2016 NAI US FDA
  • 30 August 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Bibinagar Village, India Not on file
Yadadri Bhuvanagiri District, India 3008822771

What they file, and where

Molecule Regulators Docs
Rivastigmine EDQM, US FDA 6
Tadalafil EDQM, SFDA (Saudi Arabia), US FDA 5
Ticagrelor EDQM, SFDA (Saudi Arabia), US FDA 5
Febuxostat SFDA (Saudi Arabia), US FDA 4
Perampanel SFDA (Saudi Arabia), US FDA 4
Triethylenetetramine SFDA (Saudi Arabia), US FDA 3
Asenapine US FDA 2
Atomoxetine EDQM, US FDA 2
Dimethyl SFDA (Saudi Arabia) 2
Fosfomycin US FDA 2
Show all 26 molecules on file
Parecoxib SFDA (Saudi Arabia), US FDA 2
Pioglitazone SFDA (Saudi Arabia), US FDA 2
Sildenafil SFDA (Saudi Arabia), US FDA 2
Topiramate EDQM, US FDA 2
Belumosudil US FDA 1
Cinacalcet US FDA 1
Clopidogrel US FDA 1
Clopidogrel Hydrogen Sulfate EDQM 1
Iloperidone US FDA 1
Lansoprazole US FDA 1
Pioglitazone Hydrochloride EDQM 1
Prazosin US FDA 1
Sildenafil Citrate EDQM 1
Tapentadol US FDA 1
Tapinarof US FDA 1
Vibegron US FDA 1

Also appears on these molecule pages

Febuxostat API Lansoprazole API Pioglitazone API Sildenafil API Tadalafil API Ticagrelor API Topiramate API Clopidogrel API

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 1 None

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $2.6M 22
2025 Not reported $16.1M 39
2024 Not reported $20.4M 42
2023 Not reported $14.8M 35

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. MSN Organics comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 2 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 31 March 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts